ArriVent Virtual Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
| DATE: | June 23, 2025 |
|---|---|
| TIME: | 8:00 AM EDT |
| LOCATION: | Virtual |
About The Event
Join ArriVent for a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC).